S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:BLFS

BioLife Solutions (BLFS) Stock Forecast, Price & News

$13.15
+0.47 (+3.71%)
(As of 09/22/2023 ET)
Compare
Today's Range
$12.70
$13.28
50-Day Range
$10.81
$20.35
52-Week Range
$10.48
$26.89
Volume
353,857 shs
Average Volume
510,966 shs
Market Capitalization
$571.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.60

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.1% Upside
$24.60 Price Target
Short Interest
Bearish
7.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of BioLife Solutions in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$771,738 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.02) to $0.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

585th out of 965 stocks

Electromedical Equipment Industry

11th out of 22 stocks


BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Price History

BLFS Stock News Headlines

BioLife Solutions (NASDAQ:BLFS) Trading Up 4.3%
BioLife Solutions (NASDAQ: BLFS)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
BioLife Hit By An Inventory Correction
Why Shares of BioLife Solutions Plummeted This Week
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
BioLife Solutions (BLFS) Gets a Buy from Maxim Group
8-K: BIOLIFE SOLUTIONS INC
Q1 2023 BioLife Solutions Inc Earnings Call
Biolife Solutions earnings: here's what Wall Street expects
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
466
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.60
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+87.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-139,800,000.00
Pretax Margin
-51.79%

Debt

Sales & Book Value

Annual Sales
$161.76 million
Book Value
$8.52 per share

Miscellaneous

Free Float
42,316,000
Market Cap
$571.89 million
Optionable
Not Optionable
Beta
1.65
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Michael P. RiceMr. Michael P. Rice (Age 60)
    Chairman & CEO
    Comp: $1.03M
  • Mr. Troy  WichtermanMr. Troy Wichterman (Age 38)
    Chief Financial Officer
    Comp: $508.89k
  • Dr. Aby J. Mathew Ph.D. (Age 51)
    Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer
    Comp: $543.46k
  • Ms. Karen  FosterMs. Karen Foster (Age 63)
    Chief Quality Officer
    Comp: $452.95k
  • Mr. Geraint Phillips
    Sr. VP of Global Operations
  • Mr. Todd  BerardMr. Todd Berard (Age 54)
    Chief Marketing Officer
  • Ms. Sarah  Aebersold J.D.Ms. Sarah Aebersold J.D. (Age 46)
    Chief HR Officer
  • Mr. Marcus  SchulzMr. Marcus Schulz (Age 44)
    Chief Revenue Officer













BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2023?

5 brokers have issued twelve-month price targets for BioLife Solutions' stock. Their BLFS share price forecasts range from $22.00 to $28.00. On average, they predict the company's stock price to reach $24.60 in the next year. This suggests a possible upside of 87.1% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2023?

BioLife Solutions' stock was trading at $18.20 on January 1st, 2023. Since then, BLFS shares have decreased by 27.7% and is now trading at $13.15.
View the best growth stocks for 2023 here
.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a increase in short interest in August. As of August 31st, there was short interest totaling 3,170,000 shares, an increase of 5.3% from the August 15th total of 3,010,000 shares. Based on an average trading volume of 430,800 shares, the days-to-cover ratio is presently 7.4 days.
View BioLife Solutions' Short Interest
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its earnings results on Tuesday, August, 8th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.22. The medical equipment provider had revenue of $39.51 million for the quarter, compared to analyst estimates of $43.93 million. BioLife Solutions had a negative net margin of 51.20% and a negative trailing twelve-month return on equity of 9.87%.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $144.00 million-$158.00 million, compared to the consensus revenue estimate of $186.31 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional shareholders include Casdin Capital LLC (17.75%), BlackRock Inc. (12.33%), Geneva Capital Management LLC (3.59%), State Street Corp (2.65%), Palisade Capital Management LP (2.61%) and Granahan Investment Management LLC (2.17%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $13.15.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $571.89 million and generates $161.76 million in revenue each year. The medical equipment provider earns $-139,800,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 466 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -